DLL3 and neuroendocrine neoplasm: Recent advancements in novel therapies, including peptide receptor radionuclide therapy (PRRT) and Delta-like ligand 3 (DLL3) bispecific T-cell engager (BiTE) therapies, are also promising treatment strategies for neuroendocrine tumors [10,11].